Key result
Dual GLP-1R/GCGR agonists reduce body weight by ~7% vs placebo in cardiometabolic disease.
Why the study?
Selective GLP-1R agonists improve cardiometabolic risk factors, but whether dual GLP-1R and GCGR agonism modifies these effects remains unclear.
Do dual GLP-1R/GCGR agonists reduce body weight and improve cardiometabolic risk factors in adults with cardiometabolic disease compared to placebo or selective GLP-1R agonists?
Meta-Analysis (n=6,611)
Do dual GLP-1R/GCGR agonists reduce body weight and improve cardiometabolic risk factors in adults with cardiometabolic disease compared to placebo or selective GLP-1R agonists?
Mean Difference: -7.44 (95% CI -9.44–-5.43)
Dual GLP-1R/GCGR agonists significantly reduce body weight and improve cardiometabolic risk factors, including greater triglyceride reduction compared to selective GLP-1R agonists.
Dual GLP-1R/GCGR agonism may augment cardiometabolic benefits; extends single-receptor agonist data from prior RCTs.
OBJECTIVE: Selective glucagon-like protein 1 receptor (GLP-1R) agonists reduce body weight and improve cardiometabolic risk factors. However, whether dual GLP-1R and glucagon receptor (GCGR) agonism modifies these cardiometabolic effects remains unclear. Here, we assessed the effects of dual GLP-1R/GCGR agonists on cardiometabolic risk factors across randomized controlled trials. RESEARCH DESIGN AND METHODS: In this random-effects meta-analysis, Medical Literature Analysis and Retrieval System Online (MEDLINE), Embase, and Cochran Central Register of Controlled Trials (CENTRAL) were searched from database inception to 21 June 2026 for randomized controlled trials evaluating clinical efficacy of dual GLP-1R/GCGR agonists in adults with cardiometabolic disease with a treatment duration ≥12 weeks. The primary outcome was placebo-corrected change in body weight from baseline to end of treatment. Secondary outcomes were changes in waist circumference, atherogenic lipids (total cholesterol, LDL cholesterol, and triglycerides), glycated hemoglobin, and hemodynamic outcomes. Prespecified subgroup analyses evaluated effect modification by dose, treatment indication, and the use of an active comparator (selective GLP-1R agonists). RESULTS: A total of 6,593 records were identified, and 16 trials comprising 6,611 participants (47.3% male) were included. Dual GLP-1R/GCGR agonists significantly reduced body weight compared with placebo (-7.44% [95% CI -9.44, -5.43]; -7.27 kg [95% CI -9.28, -5.27]). Weight loss was accompanied by improvements across all cardiometabolic risk factors. Compared with selective GLP-1R agonists, dual GLP-1R/GCGR agonists were associated with a greater reduction in triglycerides (-0.28 mmol/L [95% CI -0.50, -0.06]). CONCLUSIONS: Dual GLP-1R/GCGR agonists consistently improved cardiometabolic risk factors across randomized clinical trials and may provide metabolic benefits beyond selective GLP-1R agonists. These findings support further evaluation in large-scale outcome studies.
No takes yet. Share an insight, caveat, or question.
Roessler et al. (2026) conducted a meta-analysis in cardiometabolic disease (n=6,611). Dual GLP-1R/GCGR agonists vs. placebo was evaluated on placebo-corrected change in body weight from baseline to end of treatment (MD -7.44%, 95% CI -9.44, -5.43). Dual GLP-1R/GCGR agonists significantly reduced body weight compared with placebo (MD -7.44%; 95% CI -9.44 to -5.43) in adults with cardiometabolic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: